This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vijayalaxmi Articles by Herman, T. S. Search for Related Content PubMed PubMed Citation Articles by Vijayalaxmi, Articles by Herman, T. S. Social Bookmarking                            What's this?

Melatonin: From Basic Research to Cancer Treatment Clinics

From the Departments of Radiation Oncology and Cellular and Structural Biology, The University of Texas Health Science Center, San Antonio, TX.

Address reprint requests to Vijayalaxmi, PhD, Department of Radiation Oncology, The University of Texas Health Science Center, 7703 Floyd Curl Dr, San Antonio, TX 78229; email: vijay{at}uthscsa.edu

ABSTRACT: Melatonin, the chief secretory product of the pineal gland, is a direct free radical scavenger, an indirect antioxidant, as well as an important immunomodulatory agent. In both in vitro and in vivo investigations, melatonin protected healthy cells from radiation-induced and chemotherapeutic drug–induced toxicity. Furthermore, several clinical studies have demonstrated the potential of melatonin, either alone or in combination with traditional therapy, to yield a favorable efficacy to toxicity ratio in the treatment of human cancers. This study reviews the literature from laboratory investigations that document the antioxidant and oncostatic actions of melatonin and summarizes the evidence regarding the potential use of melatonin in cancer treatment. This study also provides rationale for the design of larger translational research–based clinical trials.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Postmenopausal Breast Cancer Risk in the Nurses' Health Study Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 74 - 79. [Abstract] [Full Text] [PDF]

				D. K. Mirick and S. Davis Melatonin as a Biomarker of Circadian Dysregulation Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3306 - 3313. [Abstract] [Full Text] [PDF]

				V. Srinivasan, D W. Spence, S. R. Pandi-Perumal, I. Trakht, and D. P. Cardinali Therapeutic Actions of Melatonin in Cancer: Possible Mechanisms Integr Cancer Ther, September 1, 2008; 7(3): 189 - 203. [Abstract] [PDF]

				E. S. Schernhammer, F. Berrino, V. Krogh, G. Secreto, A. Micheli, E. Venturelli, S. Sieri, C. T. Sempos, A. Cavalleri, H. J. Schunemann, et al. Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women J Natl Cancer Inst, June 18, 2008; 100(12): 898 - 905. [Abstract] [Full Text] [PDF]

				A. N. Viswanathan, S. E. Hankinson, and E. S. Schernhammer Night Shift Work and the Risk of Endometrial Cancer Cancer Res., November 1, 2007; 67(21): 10618 - 10622. [Abstract] [Full Text] [PDF]

				B. Jung and N. Ahmad Melatonin in cancer management: progress and promise. Cancer Res., October 15, 2006; 66(20): 9789 - 9793. [Abstract] [Full Text] [PDF]

				D. Wion, F. Berger, and N. Wion-Barbot Glioma, melatonin, and radiotherapy. Cancer Res., June 15, 2006; 66(12): 6457 - 6457. [Full Text] [PDF]

				W. J.M. Hrushesky, R. B. Sothern, W. J. Rietveld, J. Du Quiton, and M. E. Boon Season, Sun, Sex, and Cervical Cancer Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1940 - 1947. [Abstract] [Full Text] [PDF]

				E. S. Schernhammer and S. E. Hankinson Urinary Melatonin Levels and Breast Cancer Risk J Natl Cancer Inst, July 20, 2005; 97(14): 1084 - 1087. [Abstract] [Full Text] [PDF]

				D. E. Blask, R. T. Dauchy, L. A. Sauer, and J. A. Krause Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin Carcinogenesis, June 1, 2004; 25(6): 951 - 960. [Abstract] [Full Text] [PDF]

				E. S. Schernhammer, F. Laden, F. E. Speizer, W. C. Willett, D. J. Hunter, I. Kawachi, C. S. Fuchs, and G. A. Colditz Night-Shift Work and Risk of Colorectal Cancer in the Nurses' Health Study J Natl Cancer Inst, June 4, 2003; 95(11): 825 - 828. [Abstract] [Full Text] [PDF]

				A. Wolfler, P. M. Abuja, W. Linkesch, K. Schauenstein, P. M. Liebmann, Vijayalaxmi, C. R. Thomas Jr, R. J. Reiter, and T. S. Herman Questionable Benefit of Melatonin for Antioxidant Pharmacologic Therapy J. Clin. Oncol., October 1, 2002; 20(19): 4127 - 4129. [Full Text] [PDF]